Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC) S. Yamamoto,C-Y. Lin,C. Rojas,F. Rivera Herrero, D. L. W. Kwong,M-H. Chen, Y. Zhang,L. Yu,S. Shah, P. Bhagia, L. Shen,J-M. SunANNALS OF ONCOLOGY（2023）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
